130 related articles for article (PubMed ID: 38042134)
21. FOXC2 Promotes Oxaliplatin Resistance by Inducing Epithelial-Mesenchymal Transition via MAPK/ERK Signaling in Colorectal Cancer.
Chen Y; Deng G; Fu Y; Han Y; Guo C; Yin L; Cai C; Shen H; Wu S; Zeng S
Onco Targets Ther; 2020; 13():1625-1635. PubMed ID: 32110058
[TBL] [Abstract][Full Text] [Related]
22. The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology.
Lin X; Xu L; Tan H; Zhang X; Shao H; Yao L; Huang X
Heliyon; 2022 Nov; 8(11):e11305. PubMed ID: 36353164
[TBL] [Abstract][Full Text] [Related]
23. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model.
Wang W; Wu L; Zhang J; Wu H; Han E; Guo Q
Biochem Biophys Res Commun; 2017 May; 487(1):1-7. PubMed ID: 28042031
[TBL] [Abstract][Full Text] [Related]
24. The structural maintenance of chromosomes 5 is a possible biomarker for individualized treatment of colorectal cancer.
Gong X; Tian X; Xie H; Li Z
Cancer Med; 2023 Feb; 12(3):3276-3287. PubMed ID: 35894836
[TBL] [Abstract][Full Text] [Related]
25. Combination of oxaliplatin and β-carotene suppresses colorectal cancer by regulating cell cycle, apoptosis, and cancer stemness
Lee J; Heo SC; Kim Y
Nutr Res Pract; 2024 Feb; 18(1):62-77. PubMed ID: 38352212
[TBL] [Abstract][Full Text] [Related]
26. Circular RNA circ-CD44 regulates chemotherapy resistance by targeting the miR-330-5p/ABCC1 axis in colorectal cancer cells.
Zhao S; Xu F; Ji Y; Wang Y; Wei M; Zhang L
Histol Histopathol; 2023 Feb; 38(2):209-221. PubMed ID: 36106650
[TBL] [Abstract][Full Text] [Related]
27. Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer.
Zhou Y; Zhang Q; Wang M; Huang C; Yao X
Front Oncol; 2022; 12():827891. PubMed ID: 35265524
[TBL] [Abstract][Full Text] [Related]
28. The HSF1/miR-135b-5p axis induces protective autophagy to promote oxaliplatin resistance through the MUL1/ULK1 pathway in colorectal cancer.
Wang H; Wang X; Zhang H; Deng T; Liu R; Liu Y; Li H; Bai M; Ning T; Wang J; Ge S; Ba Y
Oncogene; 2021 Jul; 40(28):4695-4708. PubMed ID: 34140641
[TBL] [Abstract][Full Text] [Related]
29. Oxaliplatin derived monofunctional triazole-containing platinum(II) complex counteracts oxaliplatin-induced drug resistance in colorectal cancer.
Li Y; Sun Z; Cui Y; Zhang H; Zhang S; Wang X; Liu S; Gao Q
Bioorg Chem; 2021 Feb; 107():104636. PubMed ID: 33465670
[TBL] [Abstract][Full Text] [Related]
30. Oxaliplatin inhibits colorectal cancer progression by inhibiting CXCL11 secreted by cancer-associated fibroblasts and the CXCR3/PI3K/AKT pathway.
Lu C; Zhang C
Clin Transl Oncol; 2023 Jan; 25(1):160-172. PubMed ID: 36129606
[TBL] [Abstract][Full Text] [Related]
31. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer.
Wang K; Liu L; Zhang T; Zhu YL; Qiu F; Wu XG; Wang XL; Hu FQ; Huang J
Int J Nanomedicine; 2011; 6():3207-18. PubMed ID: 22238509
[TBL] [Abstract][Full Text] [Related]
32. IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway.
Huang C; Zhou T; Ma L; Zhao S
Biol Pharm Bull; 2023; 46(1):26-34. PubMed ID: 36596524
[TBL] [Abstract][Full Text] [Related]
33. Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K/Akt/MTOR pathway.
Li N; Zhang Z; Jiang G; Sun H; Yu D
Front Biosci (Landmark Ed); 2019 Jan; 24(2):303-312. PubMed ID: 30468657
[TBL] [Abstract][Full Text] [Related]
34. PFKFB3 Inhibition Attenuates Oxaliplatin-Induced Autophagy and Enhances Its Cytotoxicity in Colon Cancer Cells.
Yan S; Zhou N; Zhang D; Zhang K; Zheng W; Bao Y; Yang W
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671668
[TBL] [Abstract][Full Text] [Related]
35. Annexin A1 induces oxaliplatin resistance of gastric cancer through autophagy by targeting PI3K/AKT/mTOR.
Ren J; Hu Z; Niu G; Xia J; Wang X; Hong R; Gu J; Wang D; Ke C
FASEB J; 2023 Mar; 37(3):e22790. PubMed ID: 36786694
[TBL] [Abstract][Full Text] [Related]
36. Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells.
Wang M; Xiang Y; Wang R; Zhang L; Zhang H; Chen H; Luan X; Chen L
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431875
[TBL] [Abstract][Full Text] [Related]
37. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
[TBL] [Abstract][Full Text] [Related]
38. Transcription factor B-MYB activates lncRNA CCAT1 and upregulates SOCS3 to promote chemoresistance in colorectal cancer.
Liu F; Wang Y; Cao Y; Wu Z; Ma D; Cai J; Sha J; Chen Q
Chem Biol Interact; 2023 Apr; 374():110412. PubMed ID: 36812959
[TBL] [Abstract][Full Text] [Related]
39. [Synergistic effect of polysaccharide from
Li P; Yuan P; Que Y; Liu X; Wang G
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Apr; 41(4):504-513. PubMed ID: 33963708
[TBL] [Abstract][Full Text] [Related]
40. Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo.
Yang S; Li W; Sun H; Wu B; Ji F; Sun T; Chang H; Shen P; Wang Y; Zhou D
BMC Cancer; 2015 Dec; 15():969. PubMed ID: 26674205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
